Navigation path

Pharmaceuticals - Union Register


Register of orphan medicinal products


Product information

Brentuximab vedotin

EU orphan designation number: EU/3/11/939   
Active ingredient: Brentuximab vedotin
Indication: Treatment of cutaneous T-cell lymphoma
Sponsor: Takeda Pharma A/S
Dybendal Alle 10, 2630 Taastrup, Danmark
EU Centralised marketing authorisation: A centralised EU marketing authorisation has been obtained under the name ADCETRIS on 25/10/2012 with the number EU/1/12/794

   Public summary of scientific opinion     EPAR

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
13/01/2012 Orphan designation EMA/OD/100/11 (2012)125 of 11/01/2012
23/10/2013 Transfer of orphan designation EMA/OD/100/11/T/01 (2013)7105 of 21/10/2013
26/03/2015 Change of name and/or address of sponsor
7/12/2017 Other procedure